CAPN15抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using CD5 mouse mAb against K562 (1), Jurkat (2), Raji (3), and MOLT4 (4) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD5 mouse mAb (green) and negative control (red).    

  
  

The CAPN15 antibody targets calpain-15 (CAPN15), a calcium-dependent cysteine protease belonging to the calpain family, which regulates processes like cytoskeletal remodeling, cell adhesion, and signal transduction. CAPN15. also known as SOLH, is distinct from other calpains due to its unique domain structure, including a C-terminal calpain-type β-sandwich domain. It is expressed in tissues such as the gastrointestinal tract, skin, and immune cells, and has been implicated in diseases like gastric cancer, inflammatory bowel disease (IBD), and epidermal disorders.

CAPN15 antibodies are essential tools for studying its role in cellular functions and pathology. They are used in Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect CAPN15 expression, localization, and interactions. Research highlights its involvement in cell migration, apoptosis, and epithelial barrier integrity. For example, CAPN15 dysregulation is linked to disrupted cell-cell junctions in IBD or metastasis in cancers. Commercial CAPN15 antibodies are typically developed in hosts like rabbits or mice, with validation in specific applications. Researchers rely on these antibodies to explore CAPN15's mechanisms and therapeutic potential, though challenges like isoform specificity may require careful validation. Overall, CAPN15 antibodies are vital for advancing insights into its biological and clinical significance.